SMT201300108B - Nuove composizioni di 1-Ä2-(2,4-dimetilfenil solfanil)-fenilÜ piperazina - Google Patents

Nuove composizioni di 1-Ä2-(2,4-dimetilfenil solfanil)-fenilÜ piperazina

Info

Publication number
SMT201300108B
SMT201300108B SM201300108T SM201300108T SMT201300108B SM T201300108 B SMT201300108 B SM T201300108B SM 201300108 T SM201300108 T SM 201300108T SM 201300108 T SM201300108 T SM 201300108T SM T201300108 B SMT201300108 B SM T201300108B
Authority
SM
San Marino
Prior art keywords
piperazine
phenylü
sulfanil
dimethylphenyl
new compositions
Prior art date
Application number
SM201300108T
Other languages
English (en)
Italian (it)
Inventor
Astrid-Maria Hojer
Pernille Gundorf Drewes
Jens Kateb
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43628463&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201300108(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of SMT201300108B publication Critical patent/SMT201300108B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SM201300108T 2009-08-24 2013-09-30 Nuove composizioni di 1-Ä2-(2,4-dimetilfenil solfanil)-fenilÜ piperazina SMT201300108B (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23622309P 2009-08-24 2009-08-24
DKPA200900950 2009-08-24
PCT/DK2010/050216 WO2011023194A2 (en) 2009-08-24 2010-08-23 New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine

Publications (1)

Publication Number Publication Date
SMT201300108B true SMT201300108B (it) 2013-11-08

Family

ID=43628463

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201300108T SMT201300108B (it) 2009-08-24 2013-09-30 Nuove composizioni di 1-Ä2-(2,4-dimetilfenil solfanil)-fenilÜ piperazina

Country Status (32)

Country Link
US (3) US20120189697A1 (enExample)
EP (1) EP2470166B1 (enExample)
JP (1) JP2013502446A (enExample)
KR (1) KR20120065328A (enExample)
CN (1) CN102639117A (enExample)
AU (1) AU2010289022B2 (enExample)
BR (1) BR112012003280A2 (enExample)
CA (1) CA2769872A1 (enExample)
CL (1) CL2012000457A1 (enExample)
CO (1) CO6612204A2 (enExample)
CR (1) CR20120058A (enExample)
DK (1) DK2470166T3 (enExample)
DO (1) DOP2012000050A (enExample)
EA (1) EA021321B1 (enExample)
ES (1) ES2427628T3 (enExample)
GE (1) GEP20135950B (enExample)
HR (1) HRP20130819T1 (enExample)
IL (1) IL217914A0 (enExample)
MA (1) MA33598B1 (enExample)
ME (1) ME01602B (enExample)
MX (1) MX2012002199A (enExample)
NZ (1) NZ598083A (enExample)
PL (1) PL2470166T3 (enExample)
PT (1) PT2470166E (enExample)
RS (1) RS52959B (enExample)
SG (1) SG178325A1 (enExample)
SI (1) SI2470166T1 (enExample)
SM (1) SMT201300108B (enExample)
TN (1) TN2012000038A1 (enExample)
UA (1) UA105057C2 (enExample)
WO (1) WO2011023194A2 (enExample)
ZA (1) ZA201201360B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200932233A (en) 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
JP5787881B2 (ja) 2010-04-30 2015-09-30 武田薬品工業株式会社 腸溶性錠剤
WO2011136376A1 (ja) * 2010-04-30 2011-11-03 武田薬品工業株式会社 腸溶性錠剤
CN104146953A (zh) * 2014-07-24 2014-11-19 李雪梅 一种氢溴酸沃替西汀注射液
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
JO3456B1 (ar) * 2015-05-13 2020-07-05 H Lundbeck As فيروتيوكسيتين بيروجلوتامات
EP3184104B1 (en) 2015-12-23 2018-09-12 Hexal AG Pharmaceutical composition of vortioxetine hydrobromide comprising vortioxetine hydrobromide in a polyethylene oxide matrix
EP3184102A1 (en) 2015-12-23 2017-06-28 Hexal AG Pharmaceutical composition of vortioxetine hydrobromide comprising an inert core formed of an acidic reacting compound
MA45532A (fr) 2016-07-01 2019-05-08 H Lundbeck As Schémas posologiques de la vortioxétine destinés à une apparition rapide de l'effet antidépresseur
WO2018065348A1 (en) 2016-10-05 2018-04-12 Hexal Ag Novel enteric-coated tablet comprising vortioxetine
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
CN112006995A (zh) * 2020-08-14 2020-12-01 石药集团中奇制药技术（石家庄）有限公司 一种氢溴酸伏硫西汀片的制备方法
CN113350348B (zh) * 2020-11-05 2022-03-01 东南大学 一种1-二苯甲基-4-甲基哌嗪类化合物在制备保护肠道屏障完整性药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
US6866146B2 (en) 2001-10-09 2005-03-15 Christian M. Heesch Protective case for string instruments
JP2008524332A (ja) * 2004-12-20 2008-07-10 コレジウム ファーマシューティカル， インク． 睡眠傷害のための医薬組成物
ES2493466T3 (es) * 2005-05-12 2014-09-11 Abbvie Bahamas Ltd. Promotores de la apoptosis
JP5153629B2 (ja) * 2005-08-02 2013-02-27 ルピン・リミテッド 選択的セロトニン再取り込み阻害剤の新規の制御放出組成物
MY150647A (en) * 2006-06-16 2014-02-14 Lundbeck & Co As H 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
TW200848411A (en) 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TW200932233A (en) 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity

Also Published As

Publication number Publication date
EP2470166A2 (en) 2012-07-04
BR112012003280A2 (pt) 2017-05-23
US20150150867A1 (en) 2015-06-04
RS52959B (sr) 2014-02-28
KR20120065328A (ko) 2012-06-20
EP2470166B1 (en) 2013-08-14
EA201290116A1 (ru) 2012-06-29
AU2010289022A1 (en) 2012-03-08
PL2470166T3 (pl) 2013-11-29
UA105057C2 (uk) 2014-04-10
US20160256398A1 (en) 2016-09-08
SG178325A1 (en) 2012-03-29
ES2427628T3 (es) 2013-10-31
CL2012000457A1 (es) 2013-01-25
CR20120058A (es) 2012-04-26
GEP20135950B (en) 2013-10-25
CN102639117A (zh) 2012-08-15
PT2470166E (pt) 2013-10-02
WO2011023194A2 (en) 2011-03-03
AU2010289022B2 (en) 2013-03-14
DOP2012000050A (es) 2012-07-31
SI2470166T1 (sl) 2014-03-31
MX2012002199A (es) 2012-03-16
ME01602B (me) 2014-09-20
MA33598B1 (fr) 2012-09-01
IL217914A0 (en) 2012-03-29
ZA201201360B (en) 2013-05-29
US20120189697A1 (en) 2012-07-26
EA021321B1 (ru) 2015-05-29
TN2012000038A1 (en) 2013-09-19
CO6612204A2 (es) 2013-02-01
HRP20130819T1 (en) 2013-09-30
WO2011023194A3 (en) 2011-12-01
NZ598083A (en) 2013-08-30
CA2769872A1 (en) 2011-03-03
DK2470166T3 (da) 2013-09-08
JP2013502446A (ja) 2013-01-24

Similar Documents

Publication Publication Date Title
TN2012000038A1 (en) New compositions of 1-[-2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
EA201171287A1 (ru) Жидкие составы солей 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазина
MX2010008583A (es) Novedosos formas cristalinas de acido 4-[4-(2-adamantilcarbamoil)- 5-ter-butil-pirazol-1-il]benzoico.
PH12013502277A1 (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4 methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids
BRPI0820474B8 (pt) uso do composto 1-[2-(2,4-dimetil-fenil-sulfanil)-fenil]-piperazina ou de sais farmaceuticamente aceitáveis do mesmo
CO6440532A2 (es) Sales de disacarina, ácido difumárico, ácido di-1-hidroxi-2-naftoico y ácido monobenzoico del 2-(4-((2-amino-4-metil-6-(pentilamino)pirimidin-5-il)fenil)acetato de 4-(dimetilamino)butilo
IN2012DN03337A (enExample)
EA201100358A1 (ru) Дабигатран для чрескожной хирургической катетеризации сердца
EA201101147A1 (ru) Новый способ синтеза ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
CY1118886T1 (el) Θεραπευτικες χρησεις της 1-[2-(2,4-διμεθυλ-φαινυλσουλφανυλ)φαινυλ]πιπεραζινης
CO6592109A2 (es) Nueva forma cristalina de un derivado de ciclopropilbenzamida
EA201000398A1 (ru) Новый способ синтеза ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
MX2009010483A (es) 5-oxoisoxazoles como inhibidores de lipasas y fosfolipasas.
MX2010005048A (es) Acido 4-[4-(2-adamantilcarbamoil)-5-terc-butil-pirazol-1-il]benzoi c-465.
EA201000397A1 (ru) Новый способ синтеза ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
EA201000611A1 (ru) 4,4-дизамещенные пиперидины
MX2012002479A (es) Nuevos derivados de bencimidazol y su uso como agonistas del receptor x farnesoide.
TW200716653A (en) Azolopyridin-2-one derivatives as inhibitors of lipases and phospholipases
ES2544780T3 (es) Metadoxina para su uso como inhibidor de fibrosis hepática
EA201301136A2 (ru) Новый способ синтеза (2e)-3-(3,4-диметоксифенил)проп-2-еннитрила, применение в синтезе ивабрадина и его фармацевтически приемлемых кислотно-аддитивных солей
TW200716577A (en) Benzooxazol-2-one derivatives as inhibitors of lipases and phospholipases
TW200716581A (en) Benzothiazol-2-one derivatives as inhibitors of lipases and phospholipases
CY1114956T1 (el) Νεες συνθεσεις 1-[2-(2,4-διμεθυλο-φαινυλοσουλφανυλο)-φαινυλο]πιπεραζινης
EA201301020A1 (ru) Новый способ синтеза 3-(2-бром-4,5-диметоксифенил)пропаннитрила и применение в синтезе ивабрадина и его фармацевтически приемлемых кислотно-аддитивных солей
MY183976A (en) Pharmaceutical composition for oral administration with improved dissolution and/or absorption